Teva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Recommendation of “Hold” from Analysts

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has been assigned an average recommendation of “Hold” from the thirty-three ratings firms that are covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $20.11.

TEVA has been the topic of a number of recent research reports. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Monday, April 2nd. Cantor Fitzgerald set a $18.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, May 3rd. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, May 3rd. Citigroup set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Thursday, May 31st. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th.

In other news, Director Roberto Mignone bought 750,000 shares of the company’s stock in a transaction that occurred on Thursday, May 10th. The shares were acquired at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.43% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Global X Management Co. LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at $123,000. Wealthstreet Investment Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $200,000. Bristol Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $231,000. Bank Hapoalim BM bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $232,000. Finally, Diligent Investors LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $238,000. 65.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries traded down $0.56, reaching $23.14, during mid-day trading on Friday, Marketbeat Ratings reports. The company had a trading volume of 6,910,965 shares, compared to its average volume of 12,975,068. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $32.51. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $24.10 billion, a P/E ratio of 5.89, a P/E/G ratio of 2.30 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, May 3rd. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.28. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.80 billion. During the same quarter last year, the business posted $1.06 earnings per share. The company’s quarterly revenue was down 10.0% on a year-over-year basis. analysts expect that Teva Pharmaceutical Industries will post 2.58 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Price to Earnings Ratio (PE)

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply